This condition, now “trending” among patients undergoing transcatheter aortic valve replacement (TAVR), has expanded to almost all patients we treat, always with the same outcome: the prognosis is bad, so bad that it might warrant making the difficult decision of not going forward. The association between frailty and bad prognosis is easy to see and<a href="https://solaci.org/en/2018/09/11/frailty-what-happens-when-we-are-too-late-in-critical-lower-limb-ischemia/" title="Read more" >...</a>
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Flavio Ribichini, entitled “Usefulness of the functional evaluation with iFR and FFR in bifurcations to define PCI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Flavio Ribichini, entitled “New Indications”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) has a negative impact in the long run. Several reports have shown that, in high risk inoperable patients, transcatheter edge-to-edge valve repair with MitraClip is feasible, safe and has good results, but there is still a long way to go. The present study looked at 24 consecutive<a href="https://solaci.org/en/2018/08/21/more-evidence-for-mitraclip-in-high-risk-patients-with-severe-tricuspid-regurgitation/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR), both isolated or associated with other left valve diseases, has been associated with higher rates of heart failure hospitalization and of cardiovascular death. Recent studies in elderly high-risk patients who underwent percutaneous treatment of left valve disease have shown the presence of TR to be associated with<a href="https://solaci.org/en/2018/07/02/tricuspid-regurgitation-mitraclip-improves-survival/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic stenosis with cardiac failure or cardiogenic shock involves high mortality risk at short term. Surgery in these conditions is often unsafe, which leaves us with valvuloplasty, but only as a bridge to some other procedure, seeing as it is effective only for a short time. Few studies have looked into patients undergoing<a href="https://solaci.org/en/2018/06/20/urgent-emergent-tavr-a-valid-option/" title="Read more" >...</a>
All interventional cardiologists must be able to perform a pericardiocentesis. Whether we deal with a chronic total occlusion, a supposedly simple coronary angioplasty (we all have witnessed the perforation of a supposedly risk-free coronary artery), or a transcatheter aortic valve replacement (whose rise gave us another significant source of tamponades), we must all be ready<a href="https://solaci.org/en/2018/04/25/constrictive-pericarditis-after-pericardiocentesis/" title="Read more" >...</a>
The association between aortic stenosis and coronary disease is common, since both conditions share pathogenesis, risk factors, and symptoms. Transcatheter aortic valve replacement (TAVR) is currently indicated for high-risk and inoperable patients. It also appears as a valid alternative for the treatment of intermediate-risk patients, and it could soon be indicated for low-risk patients. Coronary<a href="https://solaci.org/en/2018/02/20/coronary-disease-works-as-30-day-predictor-in-tavr/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Even though the presence of paravalvular regurgitation (PVR) has been reduced, thank to greater experience and new devices, it is still frequent and has an impact in survival (especially moderate and severe PVR). Recent research has shown that mild PVR also has a negative impact. However, these data were provided<a href="https://solaci.org/en/2018/02/15/mild-leaks-tavrs-silent-enemies/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Currently, some small observational studies and a meta-analysis suggest that women experience more short-term complications after TAVR (due to higher rates of bleeding, vascular complications, and stroke), as well as less 1-year mortality. However, results are still conflicting. This work analyzed 17 studies including 8 different registries, with a total 23,303 women and 23,885 men.<a href="https://solaci.org/en/2018/02/14/who-lives-longer-after-tavr-men-or-women/" title="Read more" >...</a>